Loading
Alpha Teknova, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Mar 2026.
Alpha Teknova, Inc.: what insiders have been doing
This page follows insider dealings at Alpha Teknova, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 4 filings signed by 3 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases totalling €124k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €75k, bought by Lowell Matthew and made public on 9 March 2026. The buyers include 1 finance chief and 1 chief executive.
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 4 filings here. The full history, which starts in 2021, counts 27 purchases against 3 sales.
In the case of 2 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 9 March 2026, which is 223 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
56
Thresholds
n/a
Buy Volume
€28M
27 ops. · all time
Sell Volume
€80,610
3 ops. · all time
Who traded when
BuySaleMartha J. Demski1 sale
Matthew Lowell1 buy
Stephen Gunstream1 buy
Since the insiders bought
- +80.2%Entry US$2.58 · Close at T+90 US$4.65
- +80.2%Entry US$2.58 · Close at T+90 US$4.65
- -84.8%Entry US$24.60 · Close at T+365 US$3.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Alpha Teknova, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$9.67.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,439 of 24,148 companies
23.5
score / 100
Value25
Quality22
FCF yld-2.3%
Earn yld-4.1%
EV/EBITDA·
ROE-24%
Gross mgn33%
Net mgn-43%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$7.79
Analyst consensus
6 analystsStrong buy
US$8.00Target US$9.67(+24%)US$12.00
Income statement
RevenueUS$40.5M
Gross profitUS$13.4M33% margin
EBITDA-US$10.1M-25% margin
Net income-US$17.3M-38.4% margin
Valuation
PER (forward)-41.0x
P/Book6.7x
Beta0.86
Balance sheet & cash
Market capUS$418.2M
Total debtUS$28.3M
Free Cash Flow-US$9.8M
Debt / Equity44%
Profitability & ownership
ROE-24.2%
ROA-9.3%
% insiders9.3%
% institutions87.4%
Last declaration on 16 July 2026
Declarations56 total
12,000 shares0Common StockSEC:0001198230-26-000007:0
12,000 shares0Common StockSEC:0001198230-26-000007:1
26,000 shares@ US$2.146212.7% of flowCommon StockSEC:0001861134-26-000002:0
Canonical exit: 4 Jun 2026 (T+90)
40,000 shares@ US$2.190421.5% of flowCommon StockSEC:0001861091-26-000002:0
Canonical exit: 4 Jun 2026 (T+90)
8,000 shares@ US$5.064100.0% of flowCommon StockSEC:0001850902-25-000023:0
54,300 shares0Common StockSEC:0001850902-25-000015:0
54,300 shares0Common StockSEC:0001850902-25-000013:0
54,300 shares0Common StockSEC:0001850902-25-000010:0
5,000 shares0Common StockSEC:0001850902-25-000002:0
80,645 shares@ US$1.2424.2% of flowCommon StockSEC:0001850902-24-000021:0
Canonical exit: 10 Oct 2024 (T+90)
11,126,929 shares@ US$1.2449.2% of flowCommon StockSEC:0000950170-24-084046:0
Canonical exit: 10 Oct 2024 (T+90)
40,322 shares@ US$1.2413.1% of flowCommon StockSEC:0001850902-24-000022:0
Canonical exit: 10 Oct 2024 (T+90)
969,844 shares@ US$1.244.3% of flowCommon StockSEC:0000950170-24-084046:1
Canonical exit: 10 Oct 2024 (T+90)
20,000 shares0Common StockSEC:0001850902-24-000018:0
20,000 shares0Common StockSEC:0001850902-24-000017:0
20,000 shares0Common StockSEC:0001850902-24-000016:0
4,826 shares@ US$5.1478100.0% of flowCommon StockSEC:0001850902-24-000009:0
Canonical exit: 13 Nov 2022 (T+90)
18,815 shares0Common StockSEC:0001850902-24-000007:1
18,815 shares0Common StockSEC:0001850902-24-000007:0
18,815 shares0Common StockSEC:0001850902-24-000004:0
18,815 shares0Common StockSEC:0001850902-24-000005:0
3,587 shares@ US$1.73432.4% of flowCommon StockSEC:0001850902-23-000045:0
Canonical exit: 28 Feb 2024 (T+90)
6,917,837 shares@ US$1.8546.5% of flowCommon StockSEC:0000950170-23-049296:0
Canonical exit: 18 Dec 2023 (T+90)
27,027 shares@ US$1.85100.0% of flowCommon StockSEC:0001850902-23-000041:0
Canonical exit: 18 Dec 2023 (T+90)
25 of 56 declarations
About Alpha Teknova, Inc.
Alpha Teknova, Inc. (ticker: TKNO) is a U.S.-listed company trading on Nasdaq in the United States. From an international equity perspective, TKNO is best understood as a life-science tools and consumables business rather than a drug developer. The company produces critical reagents used in the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, with exposure to research-grade and GMP-oriented demand across cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Its offering is therefore tied to the infrastructure of modern biotech, where reliable inputs and fast turnaround can be strategically important.([ir.teknova.com](https://ir.teknova.com/))
Teknova traces its roots to 1996, and the company later became Alpha Teknova, Inc. through a 2019 merger. That history matters because it reflects a long operating record in specialized reagents and a gradual shift toward a broader, more regulated product mix. Management says the company serves more than 3,000 customers across the life-sciences continuum, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. For investors, that customer base suggests diversified end-market exposure, though still within the same biotech ecosystem.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm))
Read moreShow less
The business is organized around two primary product categories: Lab Essentials and Clinical Solutions. Teknova’s main product types are pre-poured media plates for cell growth and cloning, liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. These products are used in early research, process development, and, increasingly, in more clinically relevant workflows. A key part of the company’s competitive position is its ability to offer both standard and highly customized formulations, which can support customer retention and pricing power in specialized applications.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm))
Operationally, Alpha Teknova manufactures at its Hollister, California headquarters, where it also stores raw materials, components, and finished goods. This vertically integrated setup supports control over quality and delivery, but it also concentrates manufacturing risk in a single location. In its latest annual reporting and earnings materials, the company emphasized improving execution and commercial expansion. For full-year 2025, revenue reached $40.5 million, up 7% year over year, with Clinical Solutions revenue growing faster than Lab Essentials. The company also highlighted improving gross margin and cash usage trends, and it guided to 2026 revenue of $42 million to $44 million.([sec.gov](https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm))
From a market-positioning standpoint, TKNO competes in a niche but essential segment of the biotech supply chain. It is not a broad-line lab supplier; instead, it focuses on value-added reagents and custom formulations where technical consistency, speed, and flexibility matter. That makes the stock interesting for investors seeking small-cap exposure to the life-science enabling layer. Recent company commentary suggests management is investing in commercial capabilities with the longer-term goal of reaching adjusted EBITDA profitability by the end of 2027, which frames the current story as a combination of revenue expansion and operating leverage.([ir.teknova.com](https://ir.teknova.com/static-files/b625bbb6-9160-4450-98e2-06e7f688e30f))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
